Carnosine vs IGF-1 LR3

Dipeptide that buffers lactic acid in muscle during high-intensity exercise; chelates metal ions; prevents and reverses protein glycation; scavenges aldehyde oxidative byproducts

Carnosine is a naturally occurring dipeptide (β-alanyl-L-histidine) synthesized in skeletal muscle and other excitable tissues from β-alanine and histidine, where it functions as an intracellular pH buffer, antioxidant, and antiglycation agent that supports cellular homeostasis under metabolic stress. Its principal role in exercise physiology centers on buffering the proton accumulation associated with high-intensity anaerobic work, attenuating acidosis-driven impairment of contractile function and extending time to fatigue during supra-threshold effort. Human randomized controlled trials using β-alanine supplementation — which elevates muscle carnosine content by increasing substrate availability — have demonstrated attenuation of fatigue during repeated high-intensity exercise bouts in trained athletes, providing the primary human evidence base for carnosine's performance effects. Carnosine is available as an oral dietary supplement in many jurisdictions; the evidence base for muscle carnosine loading via oral β-alanine supplementation is established in human RCTs, while direct exogenous carnosine administration by injection remains investigational with no regulatory approval or established clinical evidence base.

Long-acting analog of IGF-1 that binds to IGF-1 receptors, promoting muscle protein synthesis, cellular growth, and recovery. Suppresses myostatin activity and has a significantly extended half-life compared to native IGF-1 due to reduced binding protein affinity.

IGF-1-LR3 (Long Arg3 IGF-1) is a synthetic 83-amino-acid analog of insulin-like growth factor 1, engineered with an N-terminal 13-amino-acid extension and an Arg3 substitution that substantially reduces binding to IGF-binding proteins (IGFBPs), resulting in a biological half-life approximately 120 times longer than native IGF-1 and theoretically greater receptor availability in peripheral tissues. The reduced IGFBP affinity means a higher proportion of circulating IGF-1-LR3 remains unbound and potentially bioactive; in vitro cell proliferation studies and animal models suggest amplified anabolic signaling relative to equimolar native IGF-1, and the compound is widely used as a research reagent in cell culture for controlled IGF-1R stimulation without the confounding effects of endogenous binding protein dynamics. No human pharmacokinetic, safety, or efficacy studies of IGF-1-LR3 have been published in PubMed-indexed journals; the indexed scientific literature consists of in vitro proliferation studies, animal metabolic research, and anti-doping detection methods — a complete absence of clinical data supporting or characterizing its use in humans. IGF-1-LR3 has no FDA approval or regulatory approval in any jurisdiction; it is a research laboratory reagent and non-approved analog available through research chemical suppliers, and the complete absence of published human data means its pharmacological behavior, tissue distribution, and safety profile in humans are entirely uncharacterized. IGF-1 LR3 in research contexts: as a laboratory reagent, IGF-1-LR3 is used at nanomolar concentrations in cell culture assays to stimulate IGF-1 receptor signaling. The extended half-life (approximately 20–30 hours compared to native IGF-1's 15 minutes) is the primary reason for its use in research settings requiring sustained IGF-1R activation. In animal pharmacology studies, doses vary widely by species and model; these cannot be directly extrapolated to human dosing, and no safe or effective human dose has been established. Its extended half-life relative to native IGF-1 is also the property most frequently cited in anti-doping detection literature, where the compound has been identified in biological samples from competitive athletes. The absence of any human clinical data distinguishes IGF-1-LR3 from growth hormone secretagogues such as sermorelin, ipamorelin, or MK-677, which have documented human pharmacological profiles. Providers offering researched GH-axis peptides with clinical datasets are listed in the PeptideBase directory.